[go: up one dir, main page]

UY31403A1 - "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos". - Google Patents

"derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".

Info

Publication number
UY31403A1
UY31403A1 UY31403A UY31403A UY31403A1 UY 31403 A1 UY31403 A1 UY 31403A1 UY 31403 A UY31403 A UY 31403A UY 31403 A UY31403 A UY 31403A UY 31403 A1 UY31403 A1 UY 31403A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
novedous
etoxi
tetrazol
triazol
Prior art date
Application number
UY31403A
Other languages
English (en)
Inventor
Abdekmalik Slassi
Donald A Mcleod
Erwan Arzel
Tao Xin
Methvin Isaac
Louise Edwards
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31403A1 publication Critical patent/UY31403A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion está dirigida a nuevos compuestos, su uso en terapia y composiciones farmacéuticas que comprenden dichos nuevos compuestos.
UY31403A 2007-10-19 2008-10-17 "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos". UY31403A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
UY31403A1 true UY31403A1 (es) 2009-05-29

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31403A UY31403A1 (es) 2007-10-19 2008-10-17 "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".

Country Status (21)

Country Link
US (1) US7960422B2 (es)
EP (1) EP2231647A4 (es)
JP (1) JP2011500673A (es)
KR (1) KR20100090777A (es)
CN (1) CN101896480A (es)
AR (1) AR068921A1 (es)
AU (1) AU2008312055A1 (es)
BR (1) BRPI0818448A2 (es)
CA (1) CA2703425A1 (es)
CL (1) CL2008003085A1 (es)
CO (1) CO6321281A2 (es)
CR (1) CR11376A (es)
DO (1) DOP2010000119A (es)
EA (1) EA201000654A1 (es)
IL (1) IL204958A0 (es)
MX (1) MX2010004272A (es)
PE (1) PE20090875A1 (es)
TW (1) TW200934771A (es)
UY (1) UY31403A1 (es)
WO (1) WO2009051556A1 (es)
ZA (1) ZA201002694B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP2205609B1 (de) * 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
JP5563466B2 (ja) 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
BRPI0818006B8 (pt) * 2007-10-19 2021-05-25 Boehringer Ingelheim Int compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
SG2014014013A (en) 2008-09-22 2014-07-30 Cayman Chemical Co Inc Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2012512868A (ja) * 2008-12-18 2012-06-07 アストラゼネカ・アクチエボラーグ ３−｛４−メチル−５−［（１ｒ）−１−（２−（３−メチルフェニル−２ｈ−テトラゾール−５−イル）−エトキシ］−４ｈ−［１，２，４］トリアゾール−３−イル｝−ピリジン、４−メチル−３−メチルチオ−５−（３−ピリジル）−１，２，４−トリアゾール、および（１ｒ）−１−［２−（３−メチルフェニル）−２ｈ−テトラゾール−５−イル］エタノールの製造方法
AU2010255552A1 (en) * 2009-06-05 2012-01-12 Oslo University Hospital Hf Azole derivatives as Wtn pathway inhibitors
CA2820800A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
EP0596933A1 (en) 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AU2002341921B2 (en) 2001-10-04 2007-05-31 Merck Sharp & Dohme Corp. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7592337B2 (en) 2002-03-12 2009-09-22 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
RU2352568C9 (ru) * 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
BRPI0507498A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
RU2006127575A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538179A (en) 2004-02-18 2005-12-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
AR058807A1 (es) * 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV

Also Published As

Publication number Publication date
EA201000654A1 (ru) 2010-12-30
MX2010004272A (es) 2010-04-30
US7960422B2 (en) 2011-06-14
ZA201002694B (en) 2011-03-30
BRPI0818448A2 (pt) 2015-05-12
AR068921A1 (es) 2009-12-16
CO6321281A2 (es) 2011-09-20
TW200934771A (en) 2009-08-16
DOP2010000119A (es) 2010-05-31
US20090131454A1 (en) 2009-05-21
JP2011500673A (ja) 2011-01-06
IL204958A0 (en) 2010-11-30
CN101896480A (zh) 2010-11-24
KR20100090777A (ko) 2010-08-17
WO2009051556A1 (en) 2009-04-23
EP2231647A4 (en) 2011-08-31
AU2008312055A1 (en) 2009-04-23
EP2231647A1 (en) 2010-09-29
CL2008003085A1 (es) 2009-10-09
PE20090875A1 (es) 2009-08-08
CR11376A (es) 2010-07-19
CA2703425A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
UY28342A1 (es) Nuevos compuestos
UY30610A1 (es) Moduladores de mglur5
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
ECSP10010693A (es) Compuestos pirazólicos 436
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
ECSP088246A (es) Nuevos derivados de benzotiazolona
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
TR201906970T4 (tr) Fenilefrin ihtiva eden sıvı formülasyonlar.
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
SV2006002319A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY31427A1 (es) Derivados 1,2,4-triazol amino como moduladores de mglur5
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121120